2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
4
Neoplasms
2
Multiple Myeloma
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Myeloid, Acute
2
Testicular Neoplasms
1
Testicular Germ Cell Tumor
1
Seminoma
1
Prostate Cancer Metastatic
1
Ovarian Neoplasms
1
Neutropenia
1
Lymphoma, B-Cell
1
Hodgkin Disease
1
Endodermal Sinus Tumor
1
Central Nervous System Neoplasms
1
Castrate Resistant Prostate Cancer
1
Interventions
Melphalan
1
Lenograstim
1
1-(1-((5-methoxy-1H-indol-2-yl)carbonyl)piperidin-4-yl)-2-methylpropan-2-ol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Castrate Resistant Prostate Cancer
×
Lenograstim
×
Clear all
NCT01907009
2023-04-19
MEL-CAP
Barts & The London NHS Trust
Phase 2/3
Terminated
29 enrolled